Gilead's Viread approved in US for chronic hepatitis B
This article was originally published in Scrip
Gilead Sciences' oral anti-HIV drug Viread (tenofovir disoproxil fumarate) has been approved for the treatment of chronic hepatitis B in adults by the USFDA.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.